Interventional Study
a clinical trial in which a new drug or device is used to measure a specific outcome.
CARE and JUSTICE
JUSTICE Clinical Trial Janus kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease (JUSTICE)
Brief Description
JUSTICE is a single-center, double-blinded, randomized trial of baricitinib therapy for APOL1-associated FSGS or Hypertension Associated-CKD.
Trial Physician / Study Coordinator
Maurice Smith
Email PhoneSite Name
Duke University
300 North Duke Street, Durham, NC 27701
Sponsor
NIAHD
Study Drug
Baricitinib
Estimated enrollment
75 patients
Estimated end date
2026
Interventional Study
a clinical trial in which a new drug or device is used to measure a specific outcome.
CARE and JUSTICE
JUSTICE Clinical Trial Janus kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease (JUSTICE)
Brief Description
JUSTICE is a single-center, double-blinded, randomized trial of baricitinib therapy for APOL1-associated FSGS or Hypertension Associated-CKD.
Trial is for people with
Focal Segmental Glomerulosclerosis or clinically diagnosed HTN-CKD
Study Goal
The goal of JUSTICE clinical trial is to determine whether inhibition of APOL1 protein production by baricitinib would slow down progression of APOL1-mediated kidney disease and reduce spillage of protein in the urine.
What is involved for the Patient?
Participants will be randomized to receive baricitinib or placebo control. Urine and a small blood sample will be collected monthly to monitor kidney function. Participants will be followed for 6 months. Participants will receive compensation each month.